



**Universiteit
Leiden**
The Netherlands

Improving outcome of melanoma patients upon immunotherapy

Rozeman, E.A.

Citation

Rozeman, E. A. (2025, January 7). *Improving outcome of melanoma patients upon immunotherapy*. Retrieved from <https://hdl.handle.net/1887/4173092>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4173092>

Note: To cite this publication please use the final published version (if applicable).

Improving outcome of melanoma patients
upon immunotherapy

Elisa Antoinette (Lisette) Rozeman

COLOPHON

The work described in this thesis was performed at the Netherlands Cancer Institute- Antoni van Leeuwenhoek, Amsterdam, the Netherlands

Cover design: Lisette Rozeman, Chiel Kok
Lay-out: Lisette Rozeman
Printing: Ridderprint
ISBN: 978-94-6506-690-5

The printing of this thesis was financially supported by the Oncology Graduate School Amsterdam (OOA) and the Netherlands Cancer Institute.

© Elisa Antoinette (Lisette) Rozeman 2024, Utrecht, the Netherlands. All rights reserved. No part of this thesis may be reproduced, stored, or transmitted in any form by any means, without permission of the author.

Improving outcome of melanoma patients upon immunotherapy

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 7 januari 2025
klokke 10.00 uur

door

Elisa Antoinette Rozeman

geboren te Zwolle

in 1990

Promotoren

Prof. dr. C.U. Blank

Prof dr. J.B.A.G. Haanen

Leden promotiecommissie

Prof. dr. T.N.M. Schumacher

Dr. H.W. Kapiteijn

Prof. dr. K.P.M. Suijkerbuijk

Prof. dr. B. Neyns

Prof. dr. C. Robert

Prof. dr. A.M.M. Eggermont

Universiteit Utrecht

Vrije Universiteit Brussel

Paris-Sud University

Erasmus Universiteit Rotterdam

Teamwork makes the dream work

CONTENT

PART I INTRODUCTION IN IMMUNOTHERAPY IN MELANOMA

- Chapter 1** General introduction and outline of the thesis 11
- Chapter 2** Advanced melanoma: current treatment options, biomarkers, and future perspectives 23

PART II NEOADJUVANT IMMUNOTHERAPY IN STAGE III MELANOMA

- Chapter 3** Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma 47
- Chapter 4** Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial 71
- Chapter 5** Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma 95
- Chapter 6** Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) 119

PART III OPTIMISATION OF OUTCOMES IN ADVANCED MELANOMA

- Chapter 7** IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation 143
- Chapter 8** Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma 165

Chapter 9	Combining checkpoint inhibition and targeted therapy in melanoma	185
Chapter 10	Diagnostic performance of early increase in S100B and LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma	193
Chapter 11	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma	213
Chapter 12	Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience	231
Chapter 13	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management	243
Chapter 14	Autoantibody development under treatment with immune checkpoint inhibitors	261

PART IV CONCLUDING REMARKS

Chapter 15	General discussion and future perspectives	279
Appendices	English summary	302
	Nederlandse samenvatting	306
	List of publications	311
	Curriculum vitae	317
	Dankwoord	318